首页> Future oncology (London, England)> What is the ideal treatment for advanced non-small-cell lung cancer with PD-L1 level ≥50%? Is mono immunotherapy enough?

What is the ideal treatment for advanced non-small-cell lung cancer with PD-L1 level ≥50%? Is mono immunotherapy enough?

导出 OA

翻译打印收藏纠错

第一作者： Burak,Bilgin

第一单位： Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Department of Medical Oncology, 06800, Ankara, Turkiye.

作者： Burak,Bilgin ^[1] ; Sebnem,Yucel ^[1] ; Mehmet Ali,Nahit Sendur ^[1] ; Bulent,Yalcin ^[1]

作者单位： Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Department of Medical Oncology, 06800, Ankara, Turkiye. ^[1]

关键词 PD-L1 atezolimuzmab cemiblimab chemotherapy first line immune-checkpoint inhibition lung cancer pembrolizumab

DOI 10.1080/14796694.2024.2414731

PMID 39582298

发布时间 2026-05-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Future oncology (London, England)

2024年20卷38期

3039-3041页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Future oncology (London, England)

2024年20卷38期

3039-3041页

检索历史清除

What is the ideal treatment for advanced non-small-cell lung cancer with PD-L1 level ≥50%? Is mono immunotherapy enough?

Future oncology (London, England)

相似文献

同项目论文

Future oncology (London, England)

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

What is the ideal treatment for advanced non-small-cell lung cancer with PD-L1 level ≥50%? Is mono immunotherapy enough?

Future oncology (London, England)

相似文献

同项目论文

Future oncology (London, England)

相关期刊

检索历史清除